Provided by Tiger Trade Technology Pte. Ltd.

Cardiff Oncology, Inc.

1.61
-0.0200-1.23%
Post-market: 1.640.0300+1.86%19:49 EST
Volume:440.19K
Turnover:715.30K
Market Cap:108.45M
PE:-2.03
High:1.67
Open:1.63
Low:1.61
Close:1.63
52wk High:4.99
52wk Low:1.48
Shares:67.36M
Float Shares:65.73M
Volume Ratio:0.97
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7940
EPS(LYR):-0.9539
ROE:-102.71%
ROA:-52.99%
PB:2.22
PE(LYR):-1.69

Loading ...

Cardiff Oncology to Present at Oppenheimer Annual Healthcare Life Sciences Conference

Reuters
·
Feb 19

Cardiff Oncology Inc. Files Initial Statement of Beneficial Ownership for Chief Accounting Officer Brigitte Lindsay

Reuters
·
Feb 10

Cardiff Oncology Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 29

Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus

Benzinga_recent_news
·
Jan 28

Cardiff Oncology selloff brings attractive entry point, says H.C. Wainwright

TIPRANKS
·
Jan 28

Cardiff Oncology Reports Positive Phase 2 Results for Onvansertib in First-Line RAS-Mutated mCRC

Reuters
·
Jan 28

BUZZ-U.S. STOCKS ON THE MOVE-RTX, Kimberly-Clark, HCA Healthcare

Reuters
·
Jan 27

BUZZ-Cardiff Oncology plunges after top executives step down

Reuters
·
Jan 27

Cardiff Oncology announces CEO Erlander, CFO Levine have stepped down

TIPRANKS
·
Jan 27

Cardiff Oncology announces update from CRDF-004, Phase 2 trial of onvansertib

TIPRANKS
·
Jan 27

Cardiff Oncology Inc: Data Support Selection of 30 Mg Onvansertib Dose for Registrational Program in First-Line Ras-Mutated Mcr

THOMSON REUTERS
·
Jan 27

Cardiff Oncology Inc: Onvansertib Added to Folfiri/Bev First-Line Standard of Care Regimen Showed Dose-Dependent Improvement in Overall Response Rates

THOMSON REUTERS
·
Jan 27

Cardiff Oncology Inc - Mark Erlander and James Levine Step Down From CEO and CFO Roles

THOMSON REUTERS
·
Jan 27

Cardiff Oncology Announces Executive Leadership Changes as It Transitions to Late-Stage Clinical Development

THOMSON REUTERS
·
Jan 27

Cardiff Oncology Inc - Mani Mohindru Appointed Interim CEO of Cardiff Oncology

THOMSON REUTERS
·
Jan 27

Cardiff Oncology Announces New Clinical Data on Onvansertib in Chronic Myelomonocytic Leukemia

Reuters
·
Dec 09, 2025

Cardiff Oncology Announces Clinical Data From Investigator-Sponsored Trial With Onvansertib in Chronic Myelomonocytic Leukemia at Ash 2025

THOMSON REUTERS
·
Dec 09, 2025

Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference

Reuters
·
Dec 08, 2025

Cardiff Oncology to Present at Piper Sandler Healthcare Conference

Reuters
·
Nov 24, 2025

Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), BioLife Solutions (BLFS) and Cardiff Oncology (CRDF)

TIPRANKS
·
Nov 11, 2025